Ultra V Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
66
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Ultra V General Information
Description
Developer of medical devices and functional cosmetics designed for performing dermatology and plastic surgery. The company's products are infused with special polydioxanone, an absorbable thread used in medical applications and cosmetics, mainly focused on anti-aging products, enabling medical institutions to provide safe, effective, and painless treatments.
Contact Information
Website
www.ultrav.co.krCorporate Office
- 12th Floor, Musinsa Seongsu S1
- 62 Seongsu-iro
- Seoul
- South Korea
Corporate Office
- 12th Floor, Musinsa Seongsu S1
- 62 Seongsu-iro
- Seoul
- South Korea
Ultra V Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 3. Later Stage VC | 02-May-2025 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 10-May-2018 | Completed | Generating Revenue | |||
| 1. Seed Round | 01-Aug-2016 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Ultra V Patents
Ultra V Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026221386-A1 | Composite composition for improving skin condition or treating bone-related inflammatory diseases, and method for preparing same | Pending | 17-Apr-2025 | ||
| EP-4696338-A1 | Filler composition for chondrocyte differentiation ability and collagen activity, and preparation method therefor | Pending | 15-May-2023 | ||
| US-20260294779-A1 | Filler composition for chondrocyte differentiation ability and collagen activity, and preparation method therefor | Pending | 15-May-2023 | ||
| WO-2024237674-A1 | Filler composition for chondrocyte differentiation ability and collagen activity, and preparation method therefor | Inactive | 15-May-2023 | ||
| US-20240261211-A1 | Method for preparing filler composition for molding | Pending | 06-Feb-2023 | A61L27/18 |
Ultra V Signals
Ultra V Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Healing Paper | VC-Backed Company | Minority |
Ultra V Investments (1)
Ultra V’s most recent deal was a Corporate Asset Purchase with DNC Duck (913 Units of Land and Buildings in Goyang, South Korea) for . The deal was made on 21-Aug-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| DNC Duck (913 Units of Land and Buildings in Goyang, South Korea) | 21-Aug-2024 | Corporate Asset Purchase | Buildings and Property |
Ultra V FAQs
-
When was Ultra V founded?
Ultra V was founded in 2012.
-
Where is Ultra V headquartered?
Ultra V is headquartered in Seoul, South Korea.
-
What is the size of Ultra V?
Ultra V has 66 total employees.
-
What industry is Ultra V in?
Ultra V’s primary industry is Medical Supplies.
-
Is Ultra V a private or public company?
Ultra V is a Private company.
-
What is Ultra V’s current revenue?
The current revenue for Ultra V is .
-
Who are Ultra V’s investors?
Healing Paper has invested in Ultra V.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process